$ARDX
ARDELYX, INC. Stock $ardx

$ardx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024006393 Filed on February 22, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$46.02M	$34.36M	$124.5M
YoY Change	304.81%	-22.22%	138.61%
Cost Of Revenue	$7.128M	$5.077M	$17.80M
YoY Change	363.76%	60.56%	332.23%
Gross Profit	$38.90M	$29.29M	$106.7M
YoY Change	295.6%	-28.6%	122.02%
Gross Profit Margin	84.51%	85.23%	85.7%
Selling, General & Admin	$52.99M	$47.75M	$134.4M
YoY Change	97.72%	141.99%	75.46%
% of Gross Profit	136.25%	163.04%	126.01%
Research & Development	$10.58M	$9.524M	$35.54M
YoY Change	16.34%	4.18%	0.95%
% of Gross Profit	27.2%	32.52%	33.32%
Depreciation & Amortization	$435.0K	$362.0K	$1.292M
YoY Change	-14600.0%	232.11%	12.94%
% of Gross Profit	1.12%	1.24%	1.21%
Operating Expenses	$63.57M	$57.27M	$169.9M
YoY Change	77.1%	98.36%	382.76%
Operating Profit	-$24.68M	-$27.99M	-$63.28M
YoY Change	-5.32%	-330.47%	-0.76%
Interest Expense	$2.356M	-$1.740M	$4.950M
YoY Change	129.18%	75.58%	45.59%
% of Operating Profit
Other Income/Expense, Net	$2.339M	$1.257M	$6.630M
YoY Change	79.65%	-375.05%	306.0%
Pretax Income	-$26.40M	-$28.47M	-$65.52M
YoY Change	-1.35%	-366.19%	-2.5%
Income Tax	$121.0K	$333.0K	$547.0K
% Of Pretax Income
Net Earnings	-$26.52M	-$28.80M	-$66.07M
YoY Change	-0.95%	-369.3%	-1.7%
Net Earnings / Revenue	-57.62%	-83.82%	-53.08%
Basic Earnings Per Share	-$0.11		-$0.30
Diluted Earnings Per Share	-$0.11	-$0.12	-$0.30
COMMON SHARES
Basic Shares Outstanding	232.7M shares	232.1M shares	219.3M shares
Diluted Shares Outstanding	233.1M shares		219.3M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$202.6M	$184.3M	$184.3M
YoY Change	55.38%	48.74%	48.74%
Cash & Equivalents	$36.15M	$21.47M	$18.64M
Short-Term Investments	$166.4M	$162.8M	$162.8M
Other Short-Term Assets	$17.39M	$27.33M	$27.33M
YoY Change	-11.88%	46.33%	46.33%
Inventory	$78.86M	$49.49M	$12.45M
Prepaid Expenses
Receivables	$28.16M	$22.03M	$22.03M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$257.9M	$246.1M	$246.1M
YoY Change	54.41%	60.23%	60.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.019M	$1.009M	$6.598M
YoY Change	-7.53%	-17.5%	-37.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.503M	$3.596M	$44.87M
YoY Change	610.98%	308.17%	72.94%
Total Long-Term Assets	$84.44M	$51.47M	$51.47M
YoY Change	68.98%	41.15%	41.15%
TOTAL ASSETS
Total Short-Term Assets	$257.9M	$246.1M	$246.1M
Total Long-Term Assets	$84.44M	$51.47M	$51.47M
Total Assets	$342.4M	$297.6M	$297.6M
YoY Change	57.77%	56.57%	56.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.28M	$11.14M	$11.14M
YoY Change	64.34%	2.57%	2.57%
Accrued Expenses	$33.03M	$30.03M	$30.03M
YoY Change	64.13%	41.12%	41.12%
Deferred Revenue	$6.586M	$7.182M
YoY Change	18.77%	70.55%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$56.90M	$50.39M	$50.39M
YoY Change	-9.78%	-23.18%	-23.18%
LONG-TERM LIABILITIES
Long-Term Debt	$99.83M	$49.82M	$49.82M
YoY Change
Other Long-Term Liabilities	$34.76M	$30.55M	$30.55M
YoY Change	21.82%	16.89%	16.89%
Total Long-Term Liabilities	$134.6M	$80.37M	$80.37M
YoY Change	371.69%	207.53%	207.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$56.90M	$50.39M	$50.39M
Total Long-Term Liabilities	$134.6M	$80.37M	$80.37M
Total Liabilities	$191.5M	$130.8M	$130.8M
YoY Change	109.06%	42.54%	42.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$872.7M	-$846.2M
YoY Change	8.15%	8.47%
Common Stock	$1.024B	$1.013B
YoY Change	9.79%	15.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$150.9M	$166.8M	$166.8M
YoY Change
Total Liabilities & Shareholders Equity	$342.4M	$297.6M	$297.6M
YoY Change	57.77%	56.57%	56.57%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$26.52M	-$28.80M	-$66.07M
YoY Change	-0.95%	-369.3%	-1.7%
Depreciation, Depletion And Amortization	$435.0K	$362.0K	$1.292M
YoY Change	-14600.0%	232.11%	12.94%
Cash From Operating Activities	-$35.72M	-$8.717M	-$89.72M
YoY Change	-20.25%	-161.03%	28.09%
INVESTING ACTIVITIES
Capital Expenditures	$150.0K	$44.00K	$344.0K
YoY Change	971.43%	-20.0%	525.45%
Acquisitions
YoY Change
Other Investing Activities	-$2.422M	-$29.52M	-$130.9M
YoY Change	-75.19%	-2073.53%	-808.74%
Cash From Investing Activities	-$2.572M	-$29.57M	-$131.2M
YoY Change	-73.69%	-2151.91%	-812.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$119.2M
YoY Change			66.47%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$52.97M	25.98M	$146.3M
YoY Change	4.03%	38.31%	94.18%
NET CHANGE
Cash From Operating Activities	-$35.72M	-8.717M	-$89.72M
Cash From Investing Activities	-$2.572M	-29.57M	-$131.2M
Cash From Financing Activities	$52.97M	25.98M	$146.3M
Net Change In Cash	$14.68M	-12.30M	-$74.67M
YoY Change	-501.78%	-135.64%	-414.9%
FREE CASH FLOW
Cash From Operating Activities	-$35.72M	-$8.717M	-$89.72M
Capital Expenditures	$150.0K	$44.00K	$344.0K
Free Cash Flow	-$35.87M	-$8.761M	-$90.06M
YoY Change	-19.94%	-161.57%	28.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6630000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-65520000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-67199000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-158165000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-66067000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	75341000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-74670000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96140000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72428000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-63276000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-63759000	usd
CY2023	us-gaap	Interest Expense InterestExpense	4950000	usd
CY2022	us-gaap	Interest Expense InterestExpense	3400000	usd
CY2021	us-gaap	Interest Expense InterestExpense	4502000	usd
CY2023	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	3924000	usd
CY2022	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	1673000	usd
CY2021	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	0	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1633000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	687000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-158161000	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.52
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001437402
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity Registrant Name EntityRegistrantName	ARDELYX, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1303944
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 FIFTH AVE.
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	SUITE 210
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	WALTHAM
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02451
CY2023	dei	City Area Code CityAreaCode	510
CY2023	dei	Local Phone Number LocalPhoneNumber	745-1700
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	ARDX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	724838738	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	232686008	shares
CY2023Q4	ardx	Deferred Royalty Obligation Noncurrent DeferredRoyaltyObligationNoncurrent	20179000	usd
CY2022Q4	ardx	Deferred Royalty Obligation Noncurrent DeferredRoyaltyObligationNoncurrent	11254000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	130763000	usd
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, MA
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21470000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96140000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	162829000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	27769000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22031000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7733000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	12448000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	3282000	usd
CY2023Q4	ardx	Prepaid Commercial Manufacturing Current PrepaidCommercialManufacturingCurrent	18925000	usd
CY2022Q4	ardx	Prepaid Commercial Manufacturing Current PrepaidCommercialManufacturingCurrent	13567000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8408000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5112000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	246111000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	153603000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1009000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1223000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	37039000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	25064000	usd
CY2023Q4	ardx	Prepaid Commercial Manufacturing Non Current PrepaidCommercialManufacturingNonCurrent	4235000	usd
CY2022Q4	ardx	Prepaid Commercial Manufacturing Non Current PrepaidCommercialManufacturingNonCurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5589000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9295000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3596000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	881000	usd
CY2023Q4	us-gaap	Assets Assets	297579000	usd
CY2022Q4	us-gaap	Assets Assets	190066000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11138000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10859000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12597000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7548000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4435000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3894000	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	0	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	26711000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7182000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4211000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	15041000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	12380000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	50393000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	65603000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1725000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5855000	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	49822000	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	8644000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	9025000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	91737000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	232453190	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	232453190	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	198575016	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	198575016	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	23000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	20000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1012773000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	878500000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-846204000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-780137000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	224000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-54000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	166816000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	98329000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	297579000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	190066000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	124456000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52158000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10097000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17795000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4117000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1000000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35536000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35201000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	91140000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	134401000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	76599000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	72303000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	169937000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	111800000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	163443000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-154346000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	547000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-66067000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-67207000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	219331253	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-66067000	usd
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	278000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-48000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-65789000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-67255000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-158167000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	126112000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	819000	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	190000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	584000	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	106000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	101146000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12039000	usd
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-158165000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-158165000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	71625000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10750000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-48000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	98329000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	808000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	337000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	365000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	119236000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13530000	usd
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	278000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-66067000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	166816000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-67207000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-158165000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1292000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1144000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2807000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3624000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3457000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3085000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	13530000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	10750000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	12039000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4220000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1962000	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	283000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1260000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2930000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-685000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	678000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14298000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7231000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	502000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	21141000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28346000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
CY2023	ardx	Increase Decrease In Prepaid Commercial Manufacturing Expense IncreaseDecreaseInPrepaidCommercialManufacturingExpense	9593000	usd
CY2022	ardx	Increase Decrease In Prepaid Commercial Manufacturing Expense IncreaseDecreaseInPrepaidCommercialManufacturingExpense	4161000	usd
CY2021	ardx	Increase Decrease In Prepaid Commercial Manufacturing Expense IncreaseDecreaseInPrepaidCommercialManufacturingExpense	9406000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6035000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2299000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-502000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	279000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6582000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1349000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5049000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2126000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-250000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3928000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3491000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2853000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3691000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4138000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1386000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2590000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	8509000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	550000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89717000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70044000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-152551000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	84321000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	67000000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	125550000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	215225000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	50328000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	72735000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1798000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	344000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	55000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1867000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-131248000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18415000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	50948000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	119236000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	71625000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	101146000	usd
CY2023	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	22386000	usd
CY2022	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	26971000	usd
CY2021	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	usd
CY2023	ardx	Proceeds From Sale Of Future Royalties Net Of Issuance Costs ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts	5000000	usd
CY2022	ardx	Proceeds From Sale Of Future Royalties Net Of Issuance Costs ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts	9581000	usd
CY2021	ardx	Proceeds From Sale Of Future Royalties Net Of Issuance Costs ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1173000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	202000	usd
CY2023	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	1500000	usd
CY2022	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	0	usd
CY2021	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	0	usd
CY2023	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	usd
CY2022	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	33038000	usd
CY2021	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	19444000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	106000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	146295000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	82999000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23712000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18604000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	91032000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21470000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96140000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72428000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	4240000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2901000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	3469000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	51000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	339000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1604000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	337000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	390000	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	190000	usd
CY2023	ardx	Derivative Issued DerivativeIssued	0	usd
CY2022	ardx	Derivative Issued DerivativeIssued	375000	usd
CY2021	ardx	Derivative Issued DerivativeIssued	0	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21470000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	162605000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	280000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	56000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	162829000	usd
CY2023Q4	ardx	Investments And Cash Amortized Cost InvestmentsAndCashAmortizedCost	184075000	usd
CY2023Q4	ardx	Cash Cash Equivalents And Investments Gross Unrealized Gains CashCashEquivalentsAndInvestmentsGrossUnrealizedGains	280000	usd
CY2023Q4	ardx	Cash Cash Equivalents And Investments Gross Unrealized Losses CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses	56000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, expected demand for inventory, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div>
CY2023Q4	us-gaap	Investments And Cash InvestmentsAndCash	184300000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-846200000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We are exposed to credit risks in the event of default by the counterparties to the extent of the amount recorded in our balance sheet. Cash, cash equivalents and short-term investments are invested through banks and other financial institutions in the U.S.</span></div>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21470000	usd
CY2023	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives and Hedging Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our derivative instruments as either assets or liabilities on the balance sheet and measure them at fair value. Derivatives are adjusted to fair value through other income (expense), net in the statements of operations and comprehensive loss.</span></div>
CY2023Q4	us-gaap	Investments And Cash InvestmentsAndCash	184299000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96140000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96140000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	27823000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	60000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	27769000	usd
CY2022Q4	ardx	Investments And Cash Amortized Cost InvestmentsAndCashAmortizedCost	123963000	usd
CY2022Q4	ardx	Cash Cash Equivalents And Investments Gross Unrealized Gains CashCashEquivalentsAndInvestmentsGrossUnrealizedGains	6000	usd
CY2022Q4	ardx	Cash Cash Equivalents And Investments Gross Unrealized Losses CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses	60000	usd
CY2022Q4	us-gaap	Investments And Cash InvestmentsAndCash	123909000	usd
CY2023	ardx	Available For Sale Securities Debt Securities Current Contractual Maturities Maximum AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum	P1Y
CY2022	ardx	Available For Sale Securities Debt Securities Current Contractual Maturities Maximum AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum	P1Y
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	investment
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	investment
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	22920000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	22299000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	24582000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5324000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1985000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	723000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	49487000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	28346000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	12448000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	3282000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	37039000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	25064000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	49487000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	28346000	usd
CY2023Q4	ardx	Prepaid Commercial Manufacturing PrepaidCommercialManufacturing	23200000	usd
CY2022Q4	ardx	Prepaid Commercial Manufacturing PrepaidCommercialManufacturing	13600000	usd
CY2023Q4	ardx	Prepaid Commercial Manufacturing Non Current PrepaidCommercialManufacturingNonCurrent	4200000	usd
CY2022Q4	ardx	Prepaid Commercial Manufacturing Non Current PrepaidCommercialManufacturingNonCurrent	0	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	124456000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52158000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10097000	usd
CY2021Q4	ardx	Contract With Customer Gross To Net Sales Accruals ContractWithCustomerGrossToNetSalesAccruals	0	usd
CY2022	ardx	Contract With Customer Gross To Net Sales Provisions ContractWithCustomerGrossToNetSalesProvisions	6048000	usd
CY2022	ardx	Contract With Customer Gross To Credits Or Deductions Issued ContractWithCustomerGrossToCreditsOrDeductionsIssued	-3204000	usd
CY2022Q4	ardx	Contract With Customer Gross To Net Sales Accruals ContractWithCustomerGrossToNetSalesAccruals	2844000	usd
CY2023	ardx	Contract With Customer Gross To Net Sales Provisions ContractWithCustomerGrossToNetSalesProvisions	31335000	usd
CY2023	ardx	Contract With Customer Gross To Credits Or Deductions Issued ContractWithCustomerGrossToCreditsOrDeductionsIssued	-25551000	usd
CY2023Q4	ardx	Contract With Customer Gross To Net Sales Accruals ContractWithCustomerGrossToNetSalesAccruals	8628000	usd
CY2023	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	3900000	usd
CY2022	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	1700000	usd
CY2023	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	52475000	usd
CY2023Q4	ardx	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	0	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	52475000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	912000	usd
CY2023Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	1741000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	49822000	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	0	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	49822000	usd
CY2023	ardx	Number Of Operating Lease Arrangements NumberOfOperatingLeaseArrangements	3	lease_agreement
CY2023	us-gaap	Sublease Income SubleaseIncome	800000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5589000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9295000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4435000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3894000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1725000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5855000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6160000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9749000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.068
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.068
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	3857000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	4257000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	3671000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	4481000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	4292000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3438000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4715000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1450000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	329000	usd
CY2023Q4	ardx	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6494000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	334000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6160000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4435000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1725000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13963000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.83
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8914000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.14
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	226000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.61
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	483000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.83
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22168000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.20
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	58606000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	22168000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.20
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	58606000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12199000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.30
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	25116000	usd
CY2023Q4	us-gaap	Share Price SharePrice	6.20
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1100000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	30000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1700000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.36
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.63
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.92
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13530000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10750000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12039000	usd
CY2021	us-gaap	Restructuring Charges RestructuringCharges	6200000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11210000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10880000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10201000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9657000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1009000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1223000	usd
CY2023	us-gaap	Depreciation Depreciation	600000	usd
CY2022	us-gaap	Depreciation Depreciation	700000	usd
CY2021	us-gaap	Depreciation Depreciation	1400000	usd
CY2022	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	500000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1800000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1300000	usd
CY2023Q4	ardx	Accrued Payments Due To Third Party AccruedPaymentsDueToThirdParty	3680000	usd
CY2022Q4	ardx	Accrued Payments Due To Third Party AccruedPaymentsDueToThirdParty	3385000	usd
CY2023Q4	ardx	Accrued Gross To Net Revenue Liabilities AccruedGrossToNetRevenueLiabilities	3258000	usd
CY2022Q4	ardx	Accrued Gross To Net Revenue Liabilities AccruedGrossToNetRevenueLiabilities	1991000	usd
CY2023Q4	ardx	Accrued Contract Manufacturing Costs AccruedContractManufacturingCosts	1946000	usd
CY2022Q4	ardx	Accrued Contract Manufacturing Costs AccruedContractManufacturingCosts	1657000	usd
CY2023Q4	ardx	Accrued Sales And Marketing Expenses AccruedSalesAndMarketingExpenses	3223000	usd
CY2022Q4	ardx	Accrued Sales And Marketing Expenses AccruedSalesAndMarketingExpenses	587000	usd
CY2023Q4	ardx	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	486000	usd
CY2022Q4	ardx	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	808000	usd
CY2023Q4	ardx	Derivative Liability For Exit Fees DerivativeLiabilityForExitFees	675000	usd
CY2022Q4	ardx	Derivative Liability For Exit Fees DerivativeLiabilityForExitFees	1656000	usd
CY2023Q4	ardx	Accrued Clinical Expenses AccruedClinicalExpenses	377000	usd
CY2022Q4	ardx	Accrued Clinical Expenses AccruedClinicalExpenses	223000	usd
CY2023Q4	ardx	Accrued Non Clinical Research And Development Expenses AccruedNonClinicalResearchAndDevelopmentExpenses	30000	usd
CY2022Q4	ardx	Accrued Non Clinical Research And Development Expenses AccruedNonClinicalResearchAndDevelopmentExpenses	1188000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1366000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	885000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	15041000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	12380000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	47000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	8000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	500000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	547000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	8000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	14411000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	547000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.034
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.019
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.004
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.017
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.010
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.023
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.013
CY2023	ardx	Effective Income Tax Rate Reconciliation Foreign Withholding Tax Percent EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent	-0.008
CY2022	ardx	Effective Income Tax Rate Reconciliation Foreign Withholding Tax Percent EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent	0
CY2021	ardx	Effective Income Tax Rate Reconciliation Foreign Withholding Tax Percent EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxPercent	0
CY2023	ardx	Effective Income Tax Rate Reconciliation Tax Expense Benefit Executive Compensation Disallowed Irc Sec162m Percent EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent	-0.019
CY2022	ardx	Effective Income Tax Rate Reconciliation Tax Expense Benefit Executive Compensation Disallowed Irc Sec162m Percent EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent	-0.016
CY2021	ardx	Effective Income Tax Rate Reconciliation Tax Expense Benefit Executive Compensation Disallowed Irc Sec162m Percent EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent	-0.011
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.008
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.243
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.197
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.200
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.008
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	ardx	Deferred Tax Assets Amortization And Depreciation DeferredTaxAssetsAmortizationAndDepreciation	64919000	usd
CY2022Q4	ardx	Deferred Tax Assets Amortization And Depreciation DeferredTaxAssetsAmortizationAndDepreciation	64111000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	98702000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	86547000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	15375000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6946000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5244000	usd
CY2023Q4	ardx	Deferred Tax Assets Royalty Obligation DeferredTaxAssetsRoyaltyObligation	4907000	usd
CY2022Q4	ardx	Deferred Tax Assets Royalty Obligation DeferredTaxAssetsRoyaltyObligation	2577000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6707000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4909000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	197556000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	177799000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	196197000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	175670000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1359000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2129000	usd
CY2023Q4	ardx	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	1359000	usd
CY2022Q4	ardx	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2129000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	20500000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24075000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24426000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	23624000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	262000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	460000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1613000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	99000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	811000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	811000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	811000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	23625000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24075000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24426000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	124456000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52158000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10097000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-66067000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-67207000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-158165000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	219331000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	219331000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	158690000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	158690000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104206000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104206000	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.52
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.52
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24212000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16382000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13680000	shares
CY2023	ardx	Potential Common Shares Anti Dilutive Effect On Securities PotentialCommonSharesAntiDilutiveEffectOnSecurities	6300000	shares
CY2022	ardx	Potential Common Shares Anti Dilutive Effect On Securities PotentialCommonSharesAntiDilutiveEffectOnSecurities	600000	shares
CY2021	ardx	Potential Common Shares Anti Dilutive Effect On Securities PotentialCommonSharesAntiDilutiveEffectOnSecurities	1100000	shares
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-006393-index-headers.html	Edgar Link	pending
0001628280-24-006393-index.html	Edgar Link	pending
0001628280-24-006393.txt	Edgar Link	pending
0001628280-24-006393-xbrl.zip	Edgar Link	pending
ardelyxinc2016employmentco.htm	Edgar Link	pending
ardx-20231231.htm	Edgar Link	pending
ardx-20231231.xsd	Edgar Link	pending
ardx-20231231xex311.htm	Edgar Link	pending
ardx-20231231xex312.htm	Edgar Link	pending
ardx-20231231xex321.htm	Edgar Link	pending
ardx-20231231_g1.jpg	Edgar Link	pending
consentofindependentregist.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
policyforrecoveryoferroneo.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
ardx-20231231_def.xml	Edgar Link	unprocessable
ardx-20231231_lab.xml	Edgar Link	unprocessable
ardx-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ardx-20231231_htm.xml	Edgar Link	completed
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
thirdamendedandrestatednon.htm	Edgar Link	pending
ardx-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARDX
ARDELYX, INC. Stock $ardx

2024 Q1 Form 10-K Financial Statement

#000162828024006393 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARDX ARDELYX, INC. Stock $ardx

2024 Q1 Form 10-K Financial Statement

#000162828024006393 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARDX
ARDELYX, INC. Stock $ardx